<DOC>
	<DOCNO>NCT00001009</DOCNO>
	<brief_summary>To determine effectiveness safety dextran sulfate ( DS ) treatment patient AIDS , AIDS relate complex ( ARC ) , asymptomatic HIV infection without persistent generalize lymphadenopathy ( PGL ) , determine antiviral activity different dos DS . Although zidovudine ( AZT ) show promise prolong life patient AIDS severe ARC , significant blood toxicity . It would beneficial combine AZT another antiviral agent toxicity . DS might suitable drug since show antiviral activity HIV laboratory , preliminary study show little toxicity . Also , combination DS AZT show effective either alone .</brief_summary>
	<brief_title>A Study Dextran Sulfate HIV-Infected Patients Patients With AIDS AIDS Related Complex ( ARC )</brief_title>
	<detailed_description>Although zidovudine ( AZT ) show promise prolong life patient AIDS severe ARC , significant blood toxicity . It would beneficial combine AZT another antiviral agent toxicity . DS might suitable drug since show antiviral activity HIV laboratory , preliminary study show little toxicity . Also , combination DS AZT show effective either alone . The study begin 10 patient AIDS , 10 ARC , 10 asymptomatic HIV infection take DS mouth 3 time day 24 week . If initial dose DS tolerate without significant side effect , next group patient receive high dose . A third group patient give either high low dose depend result earlier group . Patients evaluate every week 12 week , monthly remain 16 week . Patients option continue DS entire study complete drug well tolerate . Inhaled pentamidine prevention Pneumocystis carinii pneumonia allow , investigational drug . Drug effect HIV virus , immune function , clinical condition monitor periodic evaluation .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized pentamidine prophylaxis Pneumocystis carinii pneumonia ( PCP ) . Acetaminophen . Ketoconazole . Consistently positive serum HIV p24 antigen = &gt; 70 picograms/ml , define Abbott HIV antigen test , two occasion , within 1 month prior entry , separate least 72 hour , last must within 2 week start therapy . Positive antibody HIV federally license ELISA test kit . Exclusion Criteria Patients negative HIV p24 antigen test within 1 month entry exclude . Hemophiliacs exclude . Prior Medication : Excluded within 4 week study entry : Biologic response modifier . Zidovudine ( AZT ) antiretroviral agent . Other investigational drug . Excluded within 12 week study entry : Ribavirin . Excluded : Ongoing therapy and/or prophylaxis AIDSdefining opportunistic infection . Anticoagulant drug . Systemic corticosteroid . Aspirin . Dextran sulfate . Sedatives . Barbiturates . Prior Treatment : Excluded within 2 week study entry : Transfusion . Severe diarrhea : = &gt; 5 loose watery stool per day . Significant malabsorption : &gt; 10 percent weight loss within past 3 month serum carotene &lt; 75 IU/ml vitamin A &lt; 75 IU/ml . Transfusion dependent : Requiring 2 unit blood &gt; month . Active opportunistic infection . Symptomatic visceral Kaposi 's sarcoma ( KS ) , progression KS within 1 month entry , concurrent neoplasms KS . Basal cell carcinoma skin situ carcinoma cervix . Hemorrhagic diseases hemophilia A B von Willebrand disease . Active drug alcohol abuse sufficient investigator 's opinion prevent adequate compliance study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>T-Lymphocytes</keyword>
	<keyword>HIV Antigens</keyword>
	<keyword>Dextran Sulfate</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>